Pain response in a population-based study of radium-223 (Ra223) for metastatic castration-resistant prostate cancer
Sunil Parimi(BC Cancer Agency), Scott Tyldesley(BC Cancer Agency), Katherine Sunderland(BC Cancer Agency), Vincent Lapointe, Abraham Alexander(BC Cancer Agency), François Bachand(BC Cancer Agency), Howard Pai(BC Cancer Agency), Kim N.(Asian Institute of Technology), Michael McKenzie(Provincial Health Services Authority), Robert Olson(BC Cancer Agency), Maria Aparicio(BC Cancer Agency), Graeme Duncan(BC Cancer Agency), S. Bondy(BC Cancer Agency), Erica S. Tsang(University of British Columbia)
Cited by 6
Related Papers
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2012|1.4k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.3k
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
|International Journal of Radiation Oncology*Biology*Physics|2016|736